Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    NCT00036270
Show Display Options
Download search resultsDownload the search results for:
NCT00036270 (2 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Completed
Has Results
Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane
Condition: Breast Neoplasms
Interventions: Drug: exemestane (Aromasin);   Drug: tamoxifen + exemestane
2 Completed Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer
Condition: Breast Neoplasms
Interventions: Drug: exemestane;   Drug: tamoxifen

Indicates status has not been verified in more than two years